NASDAQ:TCON TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free TCON Stock Alerts $2.29 +0.58 (+33.92%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$1.71▼$2.8950-Day Range$1.71▼$12.6252-Week Range$1.59▼$41.00Volume1.97 million shsAverage Volume248,331 shsMarket Capitalization$5.22 millionP/E RatioN/ADividend YieldN/APrice Target$60.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get TRACON Pharmaceuticals alerts: Email Address TRACON Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside2,520.1% Upside$60.00 Price TargetShort InterestHealthy32.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($4.00) to ($5.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.40 out of 5 stars 3.3 Analyst's Opinion Consensus RatingTRACON Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTRACON Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted32.67% of the outstanding shares of TRACON Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverTRACON Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TRACON Pharmaceuticals has recently decreased by 60.79%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTRACON Pharmaceuticals does not currently pay a dividend.Dividend GrowthTRACON Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TCON. Previous Next 2.4 News and Social Media Coverage News SentimentTRACON Pharmaceuticals has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for TRACON Pharmaceuticals this week, compared to 1 article on an average week.Search Interest29 people have searched for TCON on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added TRACON Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -65% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TRACON Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.27% of the stock of TRACON Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 11.61% of the stock of TRACON Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for TRACON Pharmaceuticals are expected to decrease in the coming year, from ($4.00) to ($5.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TRACON Pharmaceuticals is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TRACON Pharmaceuticals is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About TRACON Pharmaceuticals Stock (NASDAQ:TCON)TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.Read More TCON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCON Stock News HeadlinesApril 16, 2024 | americanbankingnews.comTRACON Pharmaceuticals (NASDAQ:TCON) Research Coverage Started at StockNews.comApril 10, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for TRACON Pharmaceuticals Post-Reverse Split and Envafolimab Valuation UpdateApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 10, 2024 | uk.investing.comTRACON announces 1-for-20 reverse stock splitApril 10, 2024 | investorplace.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024April 8, 2024 | marketwatch.comShares of Tracon Pharmaceuticals Tumble 22% on Reverse SplitApril 8, 2024 | finanznachrichten.deTRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces Reverse Stock SplitApril 8, 2024 | globenewswire.comTRACON Pharmaceuticals Announces Reverse Stock SplitApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 8, 2024 | americanbankingnews.comTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Expected to Post FY2025 Earnings of ($0.27) Per ShareApril 8, 2024 | americanbankingnews.comTRACON Pharmaceuticals (NASDAQ:TCON) Coverage Initiated at StockNews.comApril 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for TRACON Pharmaceuticals Amid Promising Envafolimab Trial OutlookApril 3, 2024 | msn.comTracon Pharma drops after pivotal data for cancer drugApril 3, 2024 | finance.yahoo.comTRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as PlannedMarch 13, 2024 | markets.businessinsider.comJonesTrading Reaffirms Their Hold Rating on TRACON Pharmaceuticals (TCON)March 8, 2024 | markets.businessinsider.comBuy Rating for TRACON Pharmaceuticals on Strong Financials and Promising Clinical TrialsMarch 7, 2024 | finanznachrichten.deTRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateMarch 7, 2024 | seekingalpha.comTRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call TranscriptMarch 5, 2024 | globenewswire.comTRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateMarch 4, 2024 | msn.comTracon Q4 2023 Earnings PreviewMarch 4, 2024 | benzinga.comA Preview Of TRACON Pharma's EarningsFebruary 28, 2024 | globenewswire.comTRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024February 13, 2024 | finance.yahoo.comTRACON Pharmaceuticals, Inc. (TCON)December 23, 2023 | benzinga.comTRACON Pharma Stock (NASDAQ:TCON), Guidance and ForecastDecember 21, 2023 | markets.businessinsider.comBuy Rating for TRACON Pharmaceuticals on Envafolimab’s Promising Trial Outcomes and Strong Market PotentialNovember 25, 2023 | seekingalpha.comTCON TRACON Pharmaceuticals, Inc.See More Headlines Receive TCON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/17/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TCON CUSIPN/A CIK1394319 Webwww.traconpharma.com Phone(858) 550-0780Fax858-550-0786Employees17Year FoundedN/APrice Target and Rating Average Stock Price Target$60.00 High Stock Price Target$60.00 Low Stock Price Target$60.00 Potential Upside/Downside+2,520.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($5.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,590,000.00 Net MarginsN/A Pretax Margin-29.79% Return on Equity-10.25% Return on Assets7.86% Debt Debt-to-Equity RatioN/A Current Ratio0.89 Quick Ratio0.89 Sales & Book Value Annual Sales$12.05 million Price / Sales0.43 Cash Flow$2.16 per share Price / Cash Flow1.06 Book Value($0.37) per share Price / Book-6.19Miscellaneous Outstanding Shares2,280,000Free Float2,155,000Market Cap$5.22 million OptionableNo Data Beta0.95 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Charles P. Theuer M.D. (Age 60)Ph.D., Chairman, CEO & President Comp: $646.6kMr. Scott B. Brown CPA (Age 43)M.S., Chief Financial Officer Comp: $403.1kDr. James L. Freddo (Age 69)Chief Medical Officer Mr. Ya HuangExecutive Director of Statistical ProgrammingKey CompetitorsNanoString TechnologiesNASDAQ:NSTGQKiromic BioPharmaNASDAQ:KRBPAvalon GloboCareNASDAQ:ALBTEloxx PharmaceuticalsNASDAQ:ELOXFinch Therapeutics GroupNASDAQ:FNCHView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 356,968 shares on 3/11/2024Ownership: 0.844%Vanguard Group Inc.Sold 356,968 shares on 2/15/2024Ownership: 0.844%Charles TheuerBought 199 shares on 4/26/2023Total: $2,626.80 ($13.20/share)View All Insider TransactionsView All Institutional Transactions TCON Stock Analysis - Frequently Asked Questions Should I buy or sell TRACON Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TCON shares. View TCON analyst ratings or view top-rated stocks. What is TRACON Pharmaceuticals' stock price target for 2024? 3 Wall Street research analysts have issued twelve-month price objectives for TRACON Pharmaceuticals' shares. Their TCON share price targets range from $60.00 to $60.00. On average, they expect the company's stock price to reach $60.00 in the next year. This suggests a possible upside of 2,520.1% from the stock's current price. View analysts price targets for TCON or view top-rated stocks among Wall Street analysts. How have TCON shares performed in 2024? TRACON Pharmaceuticals' stock was trading at $3.5020 at the start of the year. Since then, TCON stock has decreased by 34.6% and is now trading at $2.29. View the best growth stocks for 2024 here. Are investors shorting TRACON Pharmaceuticals? TRACON Pharmaceuticals saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 744,900 shares, a decline of 60.8% from the March 15th total of 1,900,000 shares. Based on an average daily volume of 3,400,000 shares, the days-to-cover ratio is presently 0.2 days. View TRACON Pharmaceuticals' Short Interest. When is TRACON Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TCON earnings forecast. How were TRACON Pharmaceuticals' earnings last quarter? TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its earnings results on Tuesday, March, 5th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.80. The biopharmaceutical company had revenue of $3.41 million for the quarter, compared to the consensus estimate of $3 million. When did TRACON Pharmaceuticals' stock split? TRACON Pharmaceuticals shares reverse split on the morning of Wednesday, April 10th 2024. The 1-20 reverse split was announced on Wednesday, April 10th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of TRACON Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX). When did TRACON Pharmaceuticals IPO? TRACON Pharmaceuticals (TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers. How do I buy shares of TRACON Pharmaceuticals? Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TCON) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profits[Urgent!] Generational Wealth GameplanCrypto 101 MediaThe “Perfect Storm” for GoldGold Safe ExchangeTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsBiden out June 13; Kamala won’t replace him?Paradigm PressYour Money is Not SafeAmerican AlternativeUrgent alert: open this for a huge profit potentialTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TRACON Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.